Search CRIS
CURIS INC
Nasdaq · CIK 1108205
Last close0.8
Daily change-0.03 (-3.61%)
10 Years gain-99.99%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
CRIS · STANDARD
SIC 2836 · Biological Products, (No Diagnostic Substances) · Fiscal year end 1231
Fundamental
25.7Momentum
0.0Acceleration
0.0Confidence
82.0Annual Revenue17
Quarterly Revenue67
Annual CFO17
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth0.0 / 25
Quality6.8 / 25
Capital Efficiency7.6 / 20
Balance Sheet0.0 / 15
Shareholder Economics10.0 / 10
Forward Indicators0.0 / 5
Signals
Net debt reductionNet debt declined versus the comparison period.
Share count reductionDiluted share count declined 74.8536%.
Warnings
Operating margin compression · MEDIUMOperating margin compressed by 158.6252 percentage points.
Key Metrics
Revenue Growth TTM-40.41%OK
Revenue CAGR 3Y-2.42%OK
Gross Marginn/aMISSING
Operating Margin-618.3%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC-23,245.67%OK
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y-74.85%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $9.44M | n/a | -$5.71M | -$27.20M | n/a | n/a | -60.5% | n/a | n/a | 13.16M |
| 2025 FY Dec 31, 2024 | $10.91M | n/a | -$44.54M | -$39.56M | n/a | n/a | -408.34% | n/a | n/a | 6.31M |
| 2024 FY Dec 31, 2023 | $10.02M | n/a | -$48.33M | -$38.43M | n/a | n/a | -482.21% | n/a | n/a | 5.29M |
| 2023 FY Dec 31, 2022 | $10.16M | n/a | -$53.02M | -$54.34M | -$54.75M | n/a | -521.75% | -538.8% | n/a | 4.67M |
| 2022 FY Dec 31, 2021 | $10.65M | n/a | -$42.07M | -$37.62M | -$37.62M | n/a | -395.01% | -353.26% | n/a | 91.57M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $5.93M | sum latest 4 fiscal quarters Revenue | OK | 0001108205-26-000118, 0001108205-25-000107 |
| Revenue Growth TTM | -40.41% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001108205-26-000118, 0001108205-25-000107 |
| Revenue CAGR 3Y | -2.42% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001108205-26-000043 |
| Revenue CAGR 5Y | -2.71% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001108205-26-000043 |
| Gross Profit CAGR 3Y | n/a | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | INSUFFICIENT_HISTORY | derived |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001108205-26-000118, 0001108205-25-000107 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Margin | -618.3% | Operating Income / Revenue | OK | 0001108205-26-000118, 0001108205-25-000107 |
| ROIC | -23,245.67% | NOPAT / Average Invested Capital | OK | 0001108205-26-000118, 0001108205-25-000107 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001108205-26-000118 |
| Current Ratio | 0.49x | Current Assets / Current Liabilities | OK | derived |
| Revenue per Diluted Share | $2.77 | Revenue / Diluted Shares | OK | 0001108205-26-000118, 0001108205-25-000107 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |
| Dividend Payout Ratio | n/a | Cash dividends paid / Net income | NOT_MEANINGFUL | 0001108205-26-000043 |